- 生物活性
TDN345 A 是一种 Ca2+ 拮抗剂,主要用于血管和老年痴呆疾病,例如阿尔茨海默症的研究。
- 体外研究
TDN-345 (10 μM) significantly increases the intracellular NGF content in the time-course study. TDN-345 induces NGF synthesis/secretion at the concentrations of 0.1 μM; statistically significant at 1 μM. The ED
50
is 0.88 μM.
- 体内研究
TDN-345 (0.1-1.0 mg/kg, p.o.) dose-dependently decreases the mortality and ischemic neurological deficit score when administered orally twice, 60 min before ischemia and 90 min after recirculation. Additionally, TDN-345 (0.2 or 1.0 mg/kg, p.o. once daily for 3 weeks after the onset of stroke) decreases the mortality and recurrence of stroke in SHRSP.